Cargando…
Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion
BACKGROUND: Myeloma bone disease (MBD) is a severe complication of multiple myeloma (MM) mainly due to an imbalance between enhanced osteoclast activity and reduced osteoblast function. Previous studies have demonstrated that miRNAs play a vital role in the osteogenic differentiation of mesenchymal...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011228/ https://www.ncbi.nlm.nih.gov/pubmed/33789678 http://dx.doi.org/10.1186/s12935-021-01887-y |
_version_ | 1783673206151839744 |
---|---|
author | Wu, Zheyu Zhang, Yufeng Yang, Zhiqiang Zhu, Yufan Xie, Yuanlong Zhou, Fuling Cai, Lin |
author_facet | Wu, Zheyu Zhang, Yufeng Yang, Zhiqiang Zhu, Yufan Xie, Yuanlong Zhou, Fuling Cai, Lin |
author_sort | Wu, Zheyu |
collection | PubMed |
description | BACKGROUND: Myeloma bone disease (MBD) is a severe complication of multiple myeloma (MM) mainly due to an imbalance between enhanced osteoclast activity and reduced osteoblast function. Previous studies have demonstrated that miRNAs play a vital role in the osteogenic differentiation of mesenchymal stromal cells (MSCs) in MM. However, the value of miR‑302b in MBD remains to be further elucidated. The aim of this study is to explore the role of miR‑302b in the regulation of MBD osteogenic differentiation and evaluate the potential of a new therapeutic strategy for the clinical treatment of MBD. METHOD: Our previous research demonstrated that MiR-302b belongs to the miR-302 cluster and is able to inhibit tumor growth and osteolysis in an orthotopic osteosarcoma xenograft tumor mouse model. In this study, we first transfected miR-302b mimics, miR-302b inhibitor, and miR-302b NC into MM1.S and RPMI8226 MM cells to detect the correlation between miR-302b expression in the pathological specimens and the clinicopathological features by qPCR, the target correlation between miR-302b and DKK1 by immunohistochemistry, qPCR and Western blot, and the correlation between miR-302b and the Wnt/β-catenin signaling pathway by Western blot. The effect of miR-302b on osteoblastogenesis was also studied in a subperiosteal tumorigenesis model of NOD/SCID nude mice. RESULTS: We found that increased miR-302b suppressed cell proliferation and induced cell apoptosis in RPMI 8226 and MM1.S cells. TargetScan online bioinformatic analysis predicted that miR-302b is able to bind to 3′UTR of DKK1 mRNA. Target binding of miR-302b to DKK1 was demonstrated by dual-luciferase reporter assay, qPCR, Western blot and immunohistochemistry, indicating that miR-302b is able to degrade DKK1 in RPMI 8226 and MM1.S cells. The model of co-culturing MM cells with preosteoblast MC3T3-E1 cells showed that miR-302b inhibits MM-induced suppression of osteoblast differentiation. Western blotting showed that miR-302b promotes the Wnt/β-catenin signaling pathway in MM cells. Micro-CT and immunohistochemistry results showed that miR-302b suppresses myeloma bone destruction in vivo. CONCLUSION: miR-302b is able to target DKK1 and promote the Wnt/β-catenin signaling pathway in MM. |
format | Online Article Text |
id | pubmed-8011228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80112282021-04-01 Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion Wu, Zheyu Zhang, Yufeng Yang, Zhiqiang Zhu, Yufan Xie, Yuanlong Zhou, Fuling Cai, Lin Cancer Cell Int Primary Research BACKGROUND: Myeloma bone disease (MBD) is a severe complication of multiple myeloma (MM) mainly due to an imbalance between enhanced osteoclast activity and reduced osteoblast function. Previous studies have demonstrated that miRNAs play a vital role in the osteogenic differentiation of mesenchymal stromal cells (MSCs) in MM. However, the value of miR‑302b in MBD remains to be further elucidated. The aim of this study is to explore the role of miR‑302b in the regulation of MBD osteogenic differentiation and evaluate the potential of a new therapeutic strategy for the clinical treatment of MBD. METHOD: Our previous research demonstrated that MiR-302b belongs to the miR-302 cluster and is able to inhibit tumor growth and osteolysis in an orthotopic osteosarcoma xenograft tumor mouse model. In this study, we first transfected miR-302b mimics, miR-302b inhibitor, and miR-302b NC into MM1.S and RPMI8226 MM cells to detect the correlation between miR-302b expression in the pathological specimens and the clinicopathological features by qPCR, the target correlation between miR-302b and DKK1 by immunohistochemistry, qPCR and Western blot, and the correlation between miR-302b and the Wnt/β-catenin signaling pathway by Western blot. The effect of miR-302b on osteoblastogenesis was also studied in a subperiosteal tumorigenesis model of NOD/SCID nude mice. RESULTS: We found that increased miR-302b suppressed cell proliferation and induced cell apoptosis in RPMI 8226 and MM1.S cells. TargetScan online bioinformatic analysis predicted that miR-302b is able to bind to 3′UTR of DKK1 mRNA. Target binding of miR-302b to DKK1 was demonstrated by dual-luciferase reporter assay, qPCR, Western blot and immunohistochemistry, indicating that miR-302b is able to degrade DKK1 in RPMI 8226 and MM1.S cells. The model of co-culturing MM cells with preosteoblast MC3T3-E1 cells showed that miR-302b inhibits MM-induced suppression of osteoblast differentiation. Western blotting showed that miR-302b promotes the Wnt/β-catenin signaling pathway in MM cells. Micro-CT and immunohistochemistry results showed that miR-302b suppresses myeloma bone destruction in vivo. CONCLUSION: miR-302b is able to target DKK1 and promote the Wnt/β-catenin signaling pathway in MM. BioMed Central 2021-03-31 /pmc/articles/PMC8011228/ /pubmed/33789678 http://dx.doi.org/10.1186/s12935-021-01887-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Primary Research Wu, Zheyu Zhang, Yufeng Yang, Zhiqiang Zhu, Yufan Xie, Yuanlong Zhou, Fuling Cai, Lin Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion |
title | Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion |
title_full | Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion |
title_fullStr | Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion |
title_full_unstemmed | Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion |
title_short | Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion |
title_sort | elevation of mir-302b prevents multiple myeloma cell growth and bone destruction by blocking dkk1 secretion |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011228/ https://www.ncbi.nlm.nih.gov/pubmed/33789678 http://dx.doi.org/10.1186/s12935-021-01887-y |
work_keys_str_mv | AT wuzheyu elevationofmir302bpreventsmultiplemyelomacellgrowthandbonedestructionbyblockingdkk1secretion AT zhangyufeng elevationofmir302bpreventsmultiplemyelomacellgrowthandbonedestructionbyblockingdkk1secretion AT yangzhiqiang elevationofmir302bpreventsmultiplemyelomacellgrowthandbonedestructionbyblockingdkk1secretion AT zhuyufan elevationofmir302bpreventsmultiplemyelomacellgrowthandbonedestructionbyblockingdkk1secretion AT xieyuanlong elevationofmir302bpreventsmultiplemyelomacellgrowthandbonedestructionbyblockingdkk1secretion AT zhoufuling elevationofmir302bpreventsmultiplemyelomacellgrowthandbonedestructionbyblockingdkk1secretion AT cailin elevationofmir302bpreventsmultiplemyelomacellgrowthandbonedestructionbyblockingdkk1secretion |